These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Should the presence of minimal residual disease (MRD) in morphologic complete remission alter post-remission strategy in AML? Stone RM Best Pract Res Clin Haematol; 2011 Dec; 24(4):509-14. PubMed ID: 22127313 [TBL] [Abstract][Full Text] [Related]
26. Immunophenotypic measurable residual disease (MRD) in acute myeloid leukemia: Is multicentric MRD assessment feasible? Brooimans RA; van der Velden VHJ; Boeckx N; Slomp J; Preijers F; Te Marvelde JG; Van NM; Heijs A; Huys E; van der Holt B; de Greef GE; Kelder A; Schuurhuis GJ Leuk Res; 2019 Jan; 76():39-47. PubMed ID: 30553189 [TBL] [Abstract][Full Text] [Related]
27. Challenges facing minimal residual disease testing for acute myeloid leukemia and promising strategies to overcome them. Li SQ; Chen M; Huang XY; Wang H; Chang YJ Expert Rev Hematol; 2023; 16(12):981-990. PubMed ID: 37978882 [TBL] [Abstract][Full Text] [Related]
28. Prognostic significance of flow-cytometry evaluation of minimal residual disease in children with acute myeloid leukaemia treated according to the AIEOP-AML 2002/01 study protocol. Buldini B; Rizzati F; Masetti R; Fagioli F; Menna G; Micalizzi C; Putti MC; Rizzari C; Santoro N; Zecca M; Disarò S; Rondelli R; Merli P; Pigazzi M; Pession A; Locatelli F; Basso G Br J Haematol; 2017 Apr; 177(1):116-126. PubMed ID: 28240765 [TBL] [Abstract][Full Text] [Related]
29. Prognostic impact of minimal residual disease analysis by flow cytometry in patients with acute myeloid leukemia before and after allogeneic hemopoietic stem cell transplantation. Bastos-Oreiro M; Perez-Corral A; Martínez-Laperche C; Bento L; Pascual C; Kwon M; Balsalobre P; Muñoz C; Buces E; Serrano D; Gayoso J; Buño I; Anguita J; Diéz-Martín JL Eur J Haematol; 2014 Sep; 93(3):239-46. PubMed ID: 24702162 [TBL] [Abstract][Full Text] [Related]
30. Acute Myeloid Leukemia Minimal Residual Disease Detection: The Difference from Normal Approach. Wood BL Curr Protoc Cytom; 2020 Jun; 93(1):e73. PubMed ID: 32311834 [TBL] [Abstract][Full Text] [Related]
31. [Prognostic significance of minimal residual disease detected by multiparameter flow cytometry in acute myeloid leukemia]. Wang YZ; Liu YR; Zhu HH; Wu HH; Cao H; Chan Y; Hao L; Jiang B; Huang XJ Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Jun; 17(3):551-6. PubMed ID: 19549362 [TBL] [Abstract][Full Text] [Related]
32. Flow cytometry for minimal residual disease testing in acute leukemia: opportunities and challenges. Gaipa G; Buracchi C; Biondi A Expert Rev Mol Diagn; 2018 Sep; 18(9):775-787. PubMed ID: 30047795 [TBL] [Abstract][Full Text] [Related]
33. [Prognosticating relapse risk based on multiparameter flow cytometric assessment of minimal residual disease in patients with acute myeloid leukemia]. Wan SG; Zhao H; Sun XJ; He JJ; Su L; Xu J Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Jun; 17(3):557-62. PubMed ID: 19549363 [TBL] [Abstract][Full Text] [Related]
34. Minimal Residual Disease in Acute Myeloid Leukemia: Old and New Concepts. Chea M; Rigolot L; Canali A; Vergez F Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396825 [TBL] [Abstract][Full Text] [Related]
35. CD33 expression on natural killer cells is a potential confounder for residual disease detection in acute myeloid leukemia by flow cytometry. Eckel AM; Cherian S; Miller V; Soma L Cytometry B Clin Cytom; 2020 Mar; 98(2):174-178. PubMed ID: 31622025 [TBL] [Abstract][Full Text] [Related]
36. Role of minimal residual disease in the management of acute myeloid leukemia-a case-based discussion. Coltoff A; Houldsworth J; Keyzner A; Renteria AS; Mascarenhas J Ann Hematol; 2018 Jul; 97(7):1155-1167. PubMed ID: 29704019 [TBL] [Abstract][Full Text] [Related]
37. Clinical Utility of Next-Generation Sequencing in Acute Myeloid Leukemia. Yang F; Anekpuritanang T; Press RD Mol Diagn Ther; 2020 Feb; 24(1):1-13. PubMed ID: 31848884 [TBL] [Abstract][Full Text] [Related]
38. MAGIC-DR: An interpretable machine-learning guided approach for acute myeloid leukemia measurable residual disease analysis. Shopsowitz K; Lofroth J; Chan G; Kim J; Rana M; Brinkman R; Weng A; Medvedev N; Wang X Cytometry B Clin Cytom; 2024 Jul; 106(4):239-251. PubMed ID: 38415807 [TBL] [Abstract][Full Text] [Related]
39. Measurable residual disease testing for personalized treatment of acute myeloid leukemia. Ehinger M; Pettersson L APMIS; 2019 May; 127(5):337-351. PubMed ID: 30919505 [TBL] [Abstract][Full Text] [Related]